Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Tetra Bio-Pharma Inc. (C:TBP)

Business Focus: Alternative Medicine

Log in or join to add this stock to your watch list.
Aug 12, 2019 04:05 pm ET
Tetra Bio-Pharma Engages LifeSci Advisors and LifeSci Public Relations as Strategic Partners
Tetra Bio-Pharma Inc., a leader in drug discovery and development for cannabinoid-based therapeutics, announced today the company has engaged LifeSci Advisors LLC, a leading investor relations consultancy serving life science companies, and LifeSci...
Aug 02, 2019 07:44 am ET
Tetra's Officers and Employees Participate in Private Placement
ORLEANS, ON, Aug. 2, 2019 /CNW Telbec/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") is pleased to announce that it has completed the non-brokered private placement offering (the "Private Placement") announced on July 30, in which some of the Corporation's directors, officers, consultants and employees, as well as certain of their associates, purchased an aggregate of 870,000 units ("Units") of the Corporation at a price of $0.30 per Unit for aggregate gross proceeds of $261,000.
Jul 30, 2019 08:30 am ET
Tetra's Officers and Employees Participate in Private Placement
Tetra Bio-Pharma Inc. (“Tetra” or the “Corporation”) is pleased to announce that, after successfully completing a prospectus offering for aggregate gross proceeds of $8,050,000 on July 12, 2019 (the “Unit Offering“), it now intends to complete a...
Jul 18, 2019 08:00 am ET
The New Hemp Energy Drink Will Be Offered to Consumers in 700 Additional Stores in Five Provinces
Tetra Natural Heath, a subsidiary of Tetra Bio-Pharma (TSX VENTURE: TBP) (OTCQB: TBPMF), is pleased to announce that one of the largest food and convenience store chains in North America has committed to carry the Hemp Energy Drink in over 600...
Jul 18, 2019 06:30 am ET
Tetra Bio-Pharma’s Management Post Financing Corporate Update
Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V: TBP) (OTCQB: TBPMF), a bio-pharmaceutical company engaged in cannabinoid-derived drug discovery and development, is pleased to provide investors with an update on our research, regulatory and...
Jul 16, 2019 08:00 am ET
The New Hemp Energy Drink Will Soon Be Available In More Than 500 Stores in Quebec
Tetra Natural Health Inc., a division of Tetra Bio-Pharma Inc. (TSX VENTURE: TBP) (OTCQB: TBPMF), today announced that it has signed an agreement with Distribution AB inc. for the distribution of the three flavours of the new Hemp Energy Drink in...
Jul 12, 2019 10:20 am ET
Tetra Bio-Pharma Announces Closing of Unit Offering
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/
Jul 11, 2019 10:00 am ET
Panag Pharma Receives a Repayable $500,000 Contribution from the Atlantic Canada Opportunities Agency (ACOA)
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V: TBP) (OTCQB: TBPMF), is pleased to announce that its wholly owned subsidiary Panag Pharma Inc. has received a repayable Government of Canada contribution of $500,000 through the Atlantic...
Jul 05, 2019 05:42 pm ET
Tetra Bio-Pharma Comments on Recent Trading Activity at the Request of IIROC
Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") a bio-pharmaceutical multifaceted corporation with its primary focus in cannabinoid‑based drug discovery and development (TSX-V: TBP) (OTCQB: TBPMF), wishes to confirm that the Company's...
Jun 26, 2019 07:30 am ET
Spyder Cannabis Celebrates Canada Day Weekend with Launch of New Hemp Energy Drink Line
Vaughan, Ontario--(Newsfile Corp. - June 26, 2019) - Spyder Cannabis Inc. (TSXV: SPDR) ("Spyder Cannabis" or the "Company") is excited to announce that, in celebration of Canada Day, it will launch its new Hemp Energy Drink line over the Canada Day long weekend, on June 29, across its existing Ontario locations, as well as its two brand new accessories stores in Niagara Falls and Pickering, set to open this weekend. Samples will be available at all locations.
Jun 24, 2019 04:55 pm ET
Tetra Bio-Pharma Inc. Announces Pricing of Unit Offering
/NOT FOR DISTRIBUTION TO THE UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
Jun 21, 2019 09:56 am ET
Tetra Bio-Pharma Inc. Announces Voting Results of 2019 Annual General and Special Meeting
ORLEANS, ON, June 21, 2019 /CNW Telbec/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TSX VENTURE: TBP) (OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that all matters presented for approval at the Corporation's annual general and special meeting (the "Meeting") of shareholders of the Corporation held in Montréal, province of Québec, on June 20, 2019, were approved.
Jun 19, 2019 06:18 pm ET
Tetra Bio-Pharma Inc. Announces Proposed Offering of Units
/NOT FOR DISTRIBUTION TO THE UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
Jun 18, 2019 08:00 am ET
New Hemp Energy Drink to be offered to consumers in cannabis accessory stores, vapes stores, and kiosks in Canada and the US
Tetra Natural Health, a subsidiary of Tetra Bio-Pharma (TSX VENTURE: TBP) (OTCQB: TBPMF), today announced that it has signed an exclusive agreement with Spyder Cannabis Inc. (TSX VENTURE: SPDR) (“Spyder”) to distribute the three flavors of its Hemp...
Jun 18, 2019 06:30 am ET
Tetra Bio-Pharma’s Management Provides Corporate Update Ahead of Annual General Meeting
Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V: TBP) (OTCQB: TBPMF), a bio-pharmaceutical company engaged in cannabinoid-derived drug discovery and development, is pleased to provide investors with an update on our research, regulatory and...
Jun 17, 2019 07:30 am ET
Tetra Bio-Pharma Inc. Announces Change of Annual General Meeting Time
ORLEANS, ON, June 17, 2019 /CNW Telbec/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TSXV: TBP) (OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discovery, wishes to announce a change in the previously set time for the Corporation's Meeting, which was originally scheduled for Thursday, June 20, 2019 at 2:00 p.m. (Eastern Daylight Time).
Jun 17, 2019 06:30 am ET
Tetra Bio-Pharma Announces PPP003 Program Update Following Type B Meeting With U.S. FDA
Tetra Bio-Pharma Inc., (“Tetra” or the “Company”) a leader in cannabinoid-derived drug discovery and development (TSX VENTURE:TBP) (OTCQB:TBPMF) today announced that it conducted a Type B meeting with the United States Food and Drug Administration...
Jun 14, 2019 07:23 pm ET
Tetra Bio-Pharma Inc. Announces Director Resignation
ORLEANS, ON, June 14, 2019 /CNW/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TSXV: TBP) (OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discovery, wishes to announce that Mr. Benoit Chotard has tendered his resignation as director of the Corporation, effective immediately, in order to devote time to manage his other professional commitments. Furthermore, Mr. Chotard has advised the Corporation that he will not stand for re-election to the board of directors of the Corporation. The Corporation hereby wishes to withdraw his nomination for election as a dir
Jun 11, 2019 06:30 am ET
Panag Pharma Completes Phase 3 Trial With Awaye™
Panag Pharma Inc., a subsidiary of Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V: TBP) (OTCQB: TBPMF), today announced completion of Panag 001, its Phase 3 clinical trial evaluating the safety and efficacy of Topical-A, now branded as...
May 30, 2019 06:30 am ET
Tetra Bio-Pharma to Present Key Research Findings as Part of Food and Drug Administration (FDA) Public Hearing on CBD
Tetra Bio-Pharma Inc. ("Tetra" or the "Company"), a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), will present key findings from its three Phase 1 and its Phase 2 cancer and non cancer investigational...
May 14, 2019 06:30 am ET
Tetra Bio-Pharma Announces the Retirement of Bernard Lessard and the Appointment of Sabino Di Paola as Chief Financial Officer
Tetra Bio-Pharma Inc. ("Tetra" or the "Company"), a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), today announced the retirement of Bernard Lessard as Chief Financial Officer and the appointment of...
May 09, 2019 06:30 am ET
Tetra Bio-Pharma’s Recently acquired Wholly Owned Subsidiary Panag Pharma Provides an Update on Recent Activities
PANAG Pharma Inc. (PANAG), a wholly owned subsidiary of Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V: TBP) (OTCQB: TBPMF), a bio-pharmaceutical company engaged in cannabinoid-based drug discovery and development, is pleased to provide...
May 02, 2019 07:30 pm ET
Tetra Bio-Pharma’s Subsidiary, Panag Pharma, Obtains Health Canada Authorization to Commence Its First Veterinary Clinical Study
Panag Pharma Inc. (Panag), a subsidiary of Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V: TBP) (OTCQB: TBPMF), today announced that its pilot clinical study to evaluate the tolerability and potential efficacy of its PPP003 ophthalmic drug...
May 01, 2019 05:04 pm ET
Tetra Bio-Pharma Closes the Acquisition of Panag Pharma
Tetra Bio-Pharma Inc. ("Tetra" or the "Company"), a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), is pleased to announce that it completed today the previously-announced acquisition (the...
Apr 30, 2019 08:00 am ET
Tetra Natural Health Announces The Arrival of 20 containers of Hemp Energy Drink in Canada
Tetra Natural Health, a subsidiary of Tetra Bio-Pharma (TSX VENTURE: TBP) (OTCQB: TBPMF), announces the arrival of twenty (20) containers, or more than 1.7 million cans, of its Hemp Energy Drink in Canada, the first 100% natural energy drink made...
Apr 29, 2019 06:30 am ET
Tetra Bio-Pharma and Altus Formulation Sign Joint Venture Agreement for Cannabinoid Drug Product Development
Tetra Bio-Pharma Inc. (“Tetra” or “TBP”), (TSX VENTURE: TBP) (OTCQB: TBPMF), and Altus Formulation Inc. (“Altus”) today announced the signing of a Joint Venture Agreement under which the two companies will work together to develop a series of...
Apr 18, 2019 05:50 pm ET
Tetra Bio-Pharma Shareholders Approve the Acquisition of Panag Pharma
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V: TBP) (OTCQB: TBPMF), is pleased to announce that, at a special meeting of shareholders held today (the "Meeting"), the shareholders of the Company voted in favor of an ordinary resolution...
Apr 11, 2019 06:30 am ET
Tetra Bio-Pharma and Ovensa Will Engage in a Collaboration to Tackle Brain Cancer
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V: TBP) (OTCQB: TBPMF), today announced that it has entered into a collaboration agreement with Ovensa Inc. ("Ovensa") to evaluate TRIOZAN™, a proprietary nanomedicine platform for targeted...
Apr 09, 2019 06:30 am ET
Tetra Bio-Pharma Resumes its Phase 3 Clinical Trial Program
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V: TBP) (OTCQB: TBPMF), today announced it is ready to resume its Phase 3 clinical program in advanced cancer pain patients with the objective to assess Health- Related Quality of Life (HrQoL)....
Apr 01, 2019 07:00 am ET
Tetra Bio-Pharma Announces Employment Contract Renewal of CEO Guy Chamberland
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V: TBP) (OTCQB: TBPMF), today announced that the Company has renewed its CEO Guy Chamberland’s employment agreement. “We are extremely pleased with the progress that Guy has made since joining...
Mar 27, 2019 06:30 am ET
Tetra Bio-Pharma to File PPP001 With the European Medicines Agency
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V: TBP) (OTCQB: TBPMF), today announced it is ready to submit its PPP001 cannabinoid-derived drug as a herbal medicinal product to the European Medicines Agency. The pre-marketing application of...
Mar 06, 2019 06:30 am ET
Tetra Bio-Pharma Names Vice-President, Clinical Programs and Medical Affairs to Its Leadership Team
Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TSX VENTURE: TBP) (OTCQB: TBPMF), a global leader in cannabinoid-derived drug development and discovery today announced the promotion of Aurelia De Pauw to Vice-President, Clinical Programs and...
Mar 04, 2019 06:30 am ET
Tetra Bio-Pharma and Santé Cannabis Announce Completion of the First Phase 2 Cannabis Oil Trial in Cancer and Non-Cancer Patients
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V: TBP) (OTCQB: TBPMF), a global leader in cannabinoid-derived drug development and discovery, is pleased to announce completion of the first double-blind, randomized and placebo-controlled...
Feb 26, 2019 06:00 am ET
Feb 18, 2019 08:00 am ET
The Hemp Energy Drink arrives in store!
Tetra Natural Heath, a subsidiary of Tetra Bio-Pharma (TSX VENTURE: TBP) (OTCQB: TBPMF), announces that Hemp Energy Drink cans are now available in 59 grocery stores and convenience stores in British Columbia, Alberta, and Saskatchewan. In British...
Feb 12, 2019 06:30 am ET
Tetra Bio-Pharma Provides Update on its Neuropathic and Chronic Pain Drug Development Program
Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TSX VENTURE: TBP) (OTCQB: TBPMF), a global leader in cannabinoid-derived drug development and discovery, today announced accelerated development of its second-generation drug inhalation program...
Feb 08, 2019 11:52 pm ET
Tetra Bio-Pharma Announces Stock Option Grants
Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TSX VENTURE: TBP) (OTB: TBPMF), announces today that it has granted, pursuant to the Company's stock option plan (the "Plan"), 375,000 options to officers of the Company. Each option entitles...
Feb 07, 2019 02:06 pm ET
Tetra Bio-Pharma Pursues Its Research Priorities Accelerating Other Drug Development Plans
Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TSX VENTURE: TBP) (OTB: TBPMF), a global leader in cannabinoid-derived drug development and discovery, today announced a change in their Drug Development Plan (DDP) priorities. This will allow...
Feb 05, 2019 06:30 am ET
Tetra Bio-Pharma Redefines Quality Standards for Pharmaceutical Grade Cannabis-Derived Products
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V: TBP) (OTCQB: TBPMF), today announced that it has temporarily suspended its phase 3 clinical program due to impurities found in its PPP001 investigational drug being administered to patients....
Feb 04, 2019 06:00 am ET
Crescita Therapeutics Inc.™ and Tetra Natural Health Collaborate to Enhance Transdermal Delivery of Beta-Caryophyllene in Tetra’s Dermatology Product Portfolio
Crescita Therapeutics Inc. ("Crescita") (TSX: CTX), a Canadian commercial dermatology company and Tetra Natural Health (NHP), a subsidiary of Tetra Bio-Pharma, a leader in cannabinoid-derived drug discovery and development, ("Tetra") (TSX-V: TBP)...
Jan 30, 2019 05:39 pm ET
Jan 28, 2019 06:30 am ET
Tetra Bio-Pharma Files Patent Application to Protect PPP001
Tetra Bio-Pharma Inc (“Tetra” or the “Company”) (TSX VENTURE: TBP) (OTCQB: TBPMF), a leader in cannabinoid-based drug discovery and development has announced that it filed a patent application for its PPP001 drug product. Tetra’s research has led...
Jan 14, 2019 08:00 am ET
Tetra Natural Health Adds New Leaders to its Commercial Operations
Tetra Natural Health, a subsidiary of Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE:TBP) (OTCQB:TBPMF), is pleased to announce that Mr. Derek Theriault has been hired as National Sales Director and...
Jan 10, 2019 07:00 am ET
The Lung Association - Ontario and Tetra Bio-Pharma partner to help fill the gaps in cannabis research
TORONTO, Jan. 10, 2019 /CNW/ - With the recent legalization of recreational cannabis in Canada, a major gap has been revealed, and that is a lack of scientific research on the health effects of its use – both on the recreational and medical side.
Dec 20, 2018 04:00 pm ET
Tetra Successfully Completes Phase 1 Study With Vaporized Version of PPP001
Tetra Bio-Pharma Inc. (“Tetra” or “TBP”) today announced that its Phase 1 clinical trial in healthy volunteers using vaporized PPP001 has been successfully concluded. This trial was aimed at determining the pharmacokinetics (PK) and safety of a...
Dec 11, 2018 06:30 am ET
Tetra Bio-Pharma Confirms Agreements With Multiple Suppliers
Tetra Bio-Pharma Inc. (“Tetra” or “TBP”), (TSX VENTURE: TBP) (OTCQB: TBPMF) a leader in cannabinoid-based drug discovery and development confirms its non-exclusive supply agreement for GMP-Grade THC with U.S.-based Rhodes Technologies Inc. The...
Dec 06, 2018 06:30 am ET
Tetra Bio-Pharma in Process of Filing Patent Application Exceeding its Data Protection Initial Assumption for its PPP001
Tetra Bio-Pharma Inc (“Tetra” or the “Company”) (TSX VENTURE: TBP) (OTCQB: TBPMF), a leader in cannabinoid-based drug discovery and development has announced that it is in process of filing a patent application for its PPP001 drug product.  Tetra’s...
Dec 04, 2018 12:36 pm ET
Tetra Bio-Pharma Responds to Shareholders
Tetra Bio-Pharma Inc (“Tetra” or “TBP”), (TSX VENTURE: TBP) (OTCQB: TBPMF) - Recent news regarding Aphria Inc. does not in any way affect Tetra’s business, operations, clinical and drug registration and source of supply. We are well funded to...
Dec 04, 2018 07:00 am ET
Tetra Bio-Pharma Convenes First National Medical Advisory Board
Tetra Bio-Pharma Inc (“Tetra” or “TBP”), (TSX VENTURE: TBP) (OTCQB: TBPMF), – announced that it held its first National Advisory Board meeting in Toronto, on November 30, 2018 as a platform to validate their drug development and commercial...
Dec 03, 2018 08:00 am ET
Tetra Natural Health Will Deliver 20 containers of Hemp Energy Drink to Meet Consumer Demand
Tetra Natural Heath, a subsidiary of Tetra Bio-Pharma (TSX VENTURE: TBP) (OTCQB: TBPMF), announces the delivery of twenty containers, more than 1.7 million cans of its product Hemp Energy Drink, the first hemp energy drink in Canada, to meet...
Nov 30, 2018 05:02 pm ET
Tetra Bio-Pharma Closes Financing With Aphria Inc.
Tetra Bio-Pharma Inc (“Tetra” or “TBP”), (TSX VENTURE: TBP) (OTCQB: TBPMF), has closed a private placement of units (the “Private Placement”) with its strategic partner Aphria Inc. (“Aphria”) (TSX: APHA) (NYSE: APHA). Under the Private Placement,...
Nov 27, 2018 06:30 am ET
Tetra Bio-Pharma Bolsters Intellectual Property Position and Product Pipeline
Tetra Bio-Pharma Inc. (“Tetra” or “TBP”), (TSX VENTURE: TBP) (OTCQB: TBPMF), and Altus Formulation Inc. (“Altus”) today announced the signing of a non-binding term sheet ("Term Sheet") to create a joint-venture to formulate, develop and deliver...
Nov 26, 2018 09:00 am ET
Tetra Bio-Pharma’s Dr. Chamberland Goes to Washington!
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), is pleased to update the market that Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma will be travelling to Washington, D.C....
Nov 22, 2018 06:30 am ET
Tetra Bio-Pharma Seeks Solutions for Second Hand Smoke From Cannabis
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), is pleased to update the market on its strategic partnership with Sirius Air Solutions Inc. (previously known as AES) to secure a...
Nov 20, 2018 06:30 am ET
Tetra Bio-Pharma Enters into Binding Proposal with Quantum Pharma Inc.
Tetra Bio-Pharma Inc. (“Tetra” or “TBP”), (TSX VENTURE: TBP) (OTCQB: TBPMF), and Quantum Pharma Inc. (“Quantum”) today announced the signing of a binding proposal (the "Proposal") for exclusive access to a Health Canada licensed facility (i.e.,...
Nov 15, 2018 06:30 am ET
Pilot Study to Investigate a Cannabinoid Derived Drug in Dogs 
Tetra Bio-Pharma Inc. (“Tetra” or “TBP”) (TSX VENTURE: TBP) (OTCQB: TBPMF) and Panag Pharma Inc. (“Panag”) today announced the submission of a clinical research application to the Veterinary Drugs Directorate at Health Canada. This first of a kind...
Nov 13, 2018 07:30 am ET
Tetra Bio-Pharma Promotes Steeve Néron to Senior Vice President, Marketing & Medical Affairs
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), is pleased to announce the promotion of Steeve Néron as Senior Vice President, Marketing and Medical Affairs. The Corporation...
Nov 06, 2018 06:30 am ET
Tetra Bio-Pharma Enters into Non-Binding Proposal to Acquire Panag Pharma Inc.
Tetra Bio-Pharma Inc., ("Tetra" or the "Company"),  a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), today announced it has entered into a non-binding proposal (the "Proposal") with the shareholders...
Nov 01, 2018 07:00 am ET
Tetra Natural Health Signs Exclusive Agreement for the Distribution of their Hemp Energy Drink in Canada and the USA
Tetra Natural Health Inc., a division of Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE: TBP) (OTCQB: TBPMF), today announced that it has signed a major distribution agreement with Kombucha Baby Brewing Company and its partners for...
Nov 01, 2018 06:30 am ET
Tetra Bio-Pharma Obtains Health Canada Approval to Conduct a Phase 1 Pharmacokinetic & Safety Study Using Vaporized Version of PPP001
Tetra Bio-Pharma Inc. (“Tetra” or “TBP”) today announced that is has received a “No Objection Letter” (NOL) from the Therapeutic Drug Directorate at Health Canada to conduct a Phase 1 pharmacokinetic (PK) and safety study using a vaporized version...
Oct 24, 2018 06:30 am ET
Tetra Bio-Pharma Appoints Richard Giguère Chief Executive Officer of Tetra Natural Health   
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), today announced the appointment of Richard Giguère to the position of Chief Executive Officer of Tetra Natural Health Inc. a...
Oct 16, 2018 12:22 pm ET
Statement from Tetra Bio-Pharma on the legalization of recreational cannabis
ORLEANS, ON, Oct. 16, 2018 /CNW/ - October 17th, 2018 will be remembered as one of the most significant dates in Canadian history, in our lifetime.
Oct 15, 2018 06:30 am ET
Tetra Bio-Pharma Names Dr. Guy Chamberland as Chief Executive Officer and Chief Scientific Officer
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), today announced the permanent appointment of Guy Chamberland, Ph.D., as CEO and CSO having most recently held the position of CEO...
Oct 11, 2018 06:30 am ET
Tetra Bio-Pharma’s PPP002 on Track After Type C Meeting with FDA
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), today announced it received the response letter for a Type C meeting with the United States Food and Drug Administration (FDA)...
Oct 03, 2018 06:30 am ET
Tetra Bio-Pharma Moves PPP001 Closer to Commercial Manufacturing with the Issuance of a Drug Establishment License to Ford’s Pharmacy
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), in partnership with Ford’s Family Pharmacy and Wellness Center, have developed and implemented a pharmaceutical quality system...
Sep 27, 2018 06:30 am ET
Tetra Bio-Pharma Announces PPP002 Program Update Following Type B Meeting with U.S. FDA
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), today announced that it conducted a Type B meeting with the United States Food and Drug Administration (FDA) for its...
Sep 24, 2018 06:30 am ET
Tetra Bio-Pharma Takes One Step Closer to the Commercialization of Cannabis Oil-Based Retail Products
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), has made significant progress in its clinical trial for PPP005 the cannabis oil-based capsules destined for the natural health...
Sep 20, 2018 08:30 am ET
North Bud Farms Closes $944,500 Private Placement
North Bud Farms Inc. (CSE: NBUD) (the "Corporation"), is pleased to announce the closing of a non-brokered private placement offering (the "Private Placement") consisting of 3,778,000 units ("Units"), at a price of $0.25 per Unit, for gross...
Sep 20, 2018 08:00 am ET
Tetra Bio-Pharma Announces Significant Progress on Storz & Bickel Co-Development in Treating Fibromyalgia
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), has made significant progress in its co-development partnership with Storz Bickel.  The study protocol has received approval...
Sep 19, 2018 08:00 am ET
North Bud Farms to Begin Trading on the Canadian Securities Exchange
North Bud Farms Inc. ("NORTHBUD" or the "Company") is pleased to announce that its common shares will commence trading on the Canadian Securities Exchange (“CSE”) at the opening of the market on Thursday, September 20, 2018 under the stock symbol...
Sep 13, 2018 08:00 am ET
Health Canada Reclassifies Tetra Bio-Pharma’s Inhalation Device Making it Eligible for Reimbursement
Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TSX VENTURE: TBP) (OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discovery, announced today that Health Canada has re-classified the inhalation pipe device used in the...
Sep 11, 2018 08:00 am ET
Tetra Bio-Pharma Accelerates its European Drug Registration Activities
Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TSX VENTURE: TBP) (OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discovery, announced today that it is accelerating the submission of a pre-marketing application for...
Sep 05, 2018 08:00 am ET
Tetra Bio-Pharma Secures CBD Supply Agreement for Genacol Partnership
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), is pleased to announce that it has secured a CBD supply agreement with True North Cannabis in Alberta, Canada.  Tetra Bio-Pharma...
Aug 31, 2018 05:06 pm ET
Tetra Bio-Pharma Announces Record Date for Dividend-in-Kind of North Bud Farms Shares
Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TSX VENTURE: TBP) (OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discovery, announced today that its board of directors has declared a dividend-in-kind (the...
Aug 30, 2018 08:00 am ET
Tetra Bio-Pharma Adds New Marketing Vice-President
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), is pleased to announce that Mr. Steeve Neron has joined Tetra Bio-Pharma as Vice-President, Marketing, effective August 20, 2018....
Aug 23, 2018 08:00 am ET
Tetra Bio-Pharma Targets Rare Cancers in the United States
Tetra Bio-Pharma Inc. (“Tetra” or “TBP”), today announced the submission of multiple applications for Orphan Drug Designation for cannabinoids to the U.S. Food and Drug Administration, for the treatment of various forms of rare cancers and ocular...
Aug 14, 2018 08:00 am ET
Genacol Canada Corporation and Tetra Bio-Pharma Team Up to bring Innovative Cannabinoid Treatments to Self-Care Market in Canada
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), is pleased to announce that they have concluded a Development and Commercialization agreement with Genacol Canada Corporation....
Aug 13, 2018 04:00 pm ET
Tetra Bio-Pharma Announces Initiation of Coverage by Paradigm Capital
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE:TBP) (OTCQB:TBPMF), today announced that Paradigm Capital, an independent investment banking and advisory group, based in Toronto, has initiated...
Aug 09, 2018 08:00 am ET
Health Canada Gives Green Light to Tetra Bio-Pharma’s Cannabis Vs. Fentanyl Trial
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), is pleased to announce that Health Canada has approved its protocol for a clinical trial investigating its PPP001 drug as an...
Aug 08, 2018 02:16 pm ET
Tetra Bio-Pharma’s Dr. Chamberland to Announce Health Canada’s Green Light for the Cannabis vs. Fentanyl Trial
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), is pleased to announce that Health Canada has approved its protocol for a clinical trial investigating its PPP001 drug as an...
Aug 03, 2018 08:00 am ET
Tetra Bio-Pharma Provides Extension to North Bud Farms  
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), today announced that the company has provided an extension to North Bud Farms Inc.  Tetra and North Bud Farms Inc. are working...
Jul 26, 2018 08:00 am ET
Tetra Bio-Pharma Confirms Meetings With FDA
Tetra Bio-Pharma Inc., (“Tetra” or the “Company”) a leader in cannabinoid-based drug discovery and development (TSX VENTURE:TBP) (OTCQB:TBPMF) today announced that it received two meeting granted letters from the United States Food and Drug...
Jul 19, 2018 08:00 am ET
Tetra Natural Health Announces Upcoming Launch of Hemp Energy Drink
Tetra Natural Health Inc., a division of Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP) (OTCQB:TBPMF), announced that it will be commercializing Hemp Energy Drink, a caffeinated energy drink containing hemp, that received a...
Jul 16, 2018 08:37 am ET
Tetra Bio-Pharma Targets Multi-Billion Dollar Fibromyalgia Market
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE:TBP) (OTCQB:TBPMF), today announced a co-development agreement with Storz Bickel to use a specialized medical device known as the Mighty Medic, in...
Jun 29, 2018 08:00 am ET
Tetra Bio-Pharma’s Evidence-Based Business Model Confirmed
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE:TBP) (OTCQB:TBPMF), today announced that the amendment of the Prescription Drug List (PDL) to include phyto-cannabinoids supports its evidence-based...
Jun 19, 2018 08:00 am ET
Tetra Bio-Pharma Adds a New Leader for its Commercial Operations
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE:TBP) (OTCQB:TBPMF), is pleased to announce that Mr. Richard Giguere has been hired as Executive Vice-President, Commercial Operations. He will be...
Jun 18, 2018 08:00 am ET
Tetra Bio-Pharma Takes on Fentanyl in Head to Head Trial for the Treatment of Breakthrough Pain
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE:TBP) (OTCQB:TBPMF), is pleased to announce that Santé Cannabis, the independently credentialed research organization they work with has finalized the...
Jun 13, 2018 08:00 am ET
Tetra Bio-Pharma Inc. Provides Corporate Update Ahead of Its Annual General Meeting
Tetra Bio-Pharma Inc. (“Tetra” or the “Corporation”) (TSX VENTURE:TBP) (OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to provide a Corporate Update on its programs and upcoming milestones in the...
Jun 12, 2018 09:59 am ET
Tetra Bio-Pharma Inc. Announces Changes Relating to the Nomination of its Directors
ORLEANS, ON, June 12, 2018 /CNW Telbec/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TSXV: TBP) (OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discovery, wishes to announce that Mr. André Rancourt has advised the Corporation that he will not stand for re-election to the board of directors of the Corporation due to other private business obligations to which he needs to devote his time and attention. The Corporation hereby wishes to withdraw his nomination for election as a director at the upcoming annual meeting of shareholders of the Corporation schedul
Jun 05, 2018 07:00 am ET
Tetra Bio-Pharma Inc. Strengthens Senior Management Team
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX-V:TBP) (OTCQB:TBPMF), has strengthened its management team with the promotion of V.P. Financing and Business Development Robert (Bob) Bechard to Executive Vice...
May 30, 2018 10:05 am ET
Tetra Bio-Pharma Inc. Announces Listing of Warrants
ORLEANS, ON, May 30, 2018 /CNW Telbec/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TSXV: TBP) (OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that a total of 11,500,000 common share purchase warrants (the "Warrants") of the Corporation will be listed and posted for trading under the symbol TBP.WT on the TSX Venture Exchange effective on or about June 1, 2018.
May 17, 2018 08:00 am ET
Tetra Natural Health Signs a Supply Agreement with Namaste Technologies for the Marketing and Distribution of Rx Princeps™, its Premium Medicinal Cannabis Product
Tetra Natural Health a division of Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB:TBPMF) and - Namaste Technologies Inc. (“Namaste” or the “Company”) (TSX-V:N) (FRA:M5BQ) (OTCMKTS:NXTTF) is pleased to announce that the Company...
May 17, 2018 07:30 am ET
Tetra Bio-Pharma Inc. Clarifies AGM Meeting Location
Tetra Bio-Pharma Inc. (“Tetra” or the “Corporation”) (TSX VENTURE:TBP) (OTCQB:TBPMF), wishes to clarify that the annual general meeting of shareholders of the Corporation (the “Meeting”) is to be held in the City of Montréal, Québec. The...
May 09, 2018 08:30 am ET
Dr. Guy Chamberland returns to “Stock Day” Podcast with Everett Jolly to discuss Tetra-Biopharma
Dr. Guy Chamberland, Co-Founder, Chief Scientific Officer and Interim-CEO of Tetra-Biopharma Inc. (OTCQB:TBPMF) (TSX-V:TBP) (“the Company”) joined Everett Jolly on Uptick Newswire’s “Stock Day” podcast to provide an update to investors and...
May 04, 2018 08:26 am ET
Tetra BioPharma Signs Second Commercialization Deal with Azevedos Industria Farmaceutica, S.A. for the Lead RX product PPP001
Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB:TBPMF), and Azevedos Indústria Farmacêutica, S.A. announced that they have signed a binding term sheet for the marketing and distribution of PPP001 in Portugal. This binding term...
Apr 24, 2018 08:00 am ET
Tetra Bio-Pharma Signs Landmark Commercialization Term Sheet for its Lead Pharmaceutical Product, PPP001, in Israel
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP) (OTCQB: TBPMF), announced today that the Company has signed a first binding term sheet for the marketing and distribution of PPP001 in Israel with Kamada Ltd., a leading pharmaceutical company. The signing of a Definitive Distribution Agreement is expected to follow shortly. PPP001 is being developed to be the first smokable cannabis product for advanced cancer pain available under prescription.
Apr 24, 2018 07:58 am ET
Tetra Bio-Pharma Signs Landmark Commercialization Term Sheet for its Lead Pharmaceutical Product, PPP001, in Israel
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP) (OTCQB:TBPMF), announced today that the Company has signed a first binding term sheet for the marketing and distribution of PPP001 in Israel with Kamada Ltd., a leading...
Apr 12, 2018 08:00 am ET
Tetra Bio-Pharma Clinical Study on Cannabis Oil Capsules for Patients Suffering from Chronic Pain should be completed by Fall 2018
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP) (OTCQB: TBPMF), provides a status report on its encapsulated cannabis oils (PPP005) clinical trials and that these cannabis products are ready to commercialize in the retail market post-legalization.
Apr 12, 2018 07:58 am ET
Tetra Bio-Pharma Clinical Study on Cannabis Oil Capsules for Patients Suffering from Chronic Pain should be completed by Fall 2018
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP) (OTCQB:TBPMF), provides a status report on its encapsulated cannabis oils (PPP005) clinical trials and that these cannabis products are ready to commercialize in the retail market...
Apr 10, 2018 08:00 am ET
Tetra Bio-Pharma Announces the appointment of Gregory Drohan to its board of directors
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP)(OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discovery, announced today that it has appointed Gregory Drohan to its board of directors effective April 10, 2018.
Apr 10, 2018 07:58 am ET
Tetra Bio-Pharma Announces the appointment of Gregory Drohan to its board of directors
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, announced today that it has appointed Gregory Drohan to its board of directors...
Apr 04, 2018 07:26 am ET
Tetra Bio-Pharma Initiates Enrolment of Patients in Phase 3 PPP001 Smokable Cannabis Pellet Study
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP) (OTCQB: TBPMF), today announced the initiation of screening and enrolment activities in the Phase 3 study of its PPP001 smokable cannabis pellet for advanced cancer patients with uncontrolled pain.
Apr 04, 2018 07:26 am ET
Tetra Bio-Pharma Initiates Enrolment of Patients in Phase 3 PPP001 Smokable Cannabis Pellet Study
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP) (OTCQB:TBPMF), today announced the initiation of screening and enrolment activities in the Phase 3 study of its PPP001 smokable cannabis pellet for advanced cancer patients with...
Apr 03, 2018 01:55 pm ET
Tetra Bio-Pharma Names Guy Chamberland as Interim CEO
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP)(OTCQB: TBPMF), today announced the appointment of Guy Chamberland, M.Sc., Ph.D., an accomplished drug developer, as interim Chief Executive Officer (CEO). This appointment is effective immediately.
Apr 03, 2018 01:55 pm ET
Tetra Bio-Pharma Names Guy Chamberland as Interim CEO
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), today announced the appointment of Guy Chamberland, M.Sc., Ph.D., an accomplished drug developer, as interim Chief Executive Officer (CEO). This appointment...
Mar 27, 2018 11:49 pm ET
CORRECTION FROM SOURCE: Tetra Bio-Pharma Inc. Announces the Closing of $4,292,000 Non-Brokered Private Placement
This document corrects and replaces the press release that was sent on March 27, 2018 at 7:30 PM ET.
Mar 27, 2018 11:49 pm ET
CORRECTION FROM SOURCE: Tetra Bio-Pharma Inc. Announces the Closing of $4,292,000 Non-Brokered Private Placement
This document corrects and replaces the press release that was sent on March 27, 2018 at 7:30 PM ET. Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug...
Mar 27, 2018 07:30 pm ET
Tetra Bio-Pharma Inc. Announces the Closing of $4,422,000 Non-Brokered Private Placement
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP)(OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce it has closed its non-brokered private placement of 4,422,000 units at a price of $1.00 per unit for aggregate gross proceeds of $4,422,000. Each unit consists of one common share and one non-transferable warrant, with a warrant entitling the holder to purchase one common share at a price of $1.30 per share for a period of thirty-six months expiring March 28, 2021.
Mar 27, 2018 07:28 pm ET
Tetra Bio-Pharma Inc. Announces the Closing of $4,422,000 Non-Brokered Private Placement
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce it has closed its non-brokered private placement of 4,422,000 units at a...
Mar 20, 2018 08:00 am ET
Tetra Bio-Pharma Added to Leading Cannabis ETF: Horizons Marijuana Life Sciences Index
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP)(OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that it has been added to the Horizons Marijuana Life Sciences Index (HMMJ) managed by Horizons ETFs Management (Canada) Inc.
Mar 20, 2018 07:57 am ET
Tetra Bio-Pharma Added to Leading Cannabis ETF: Horizons Marijuana Life Sciences Index
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that it has been added to the Horizons Marijuana Life Sciences Index (HMMJ)...
Mar 19, 2018 02:00 pm ET
Horizons ETFs Completes Rebalance of its Marijuana Life Sciences Index ETF
HMMJ adds 10 new stocks as part of this latest quarterly rebalancing
Mar 19, 2018 08:01 am ET
Tetra Bio-Pharma Completes Acquisition of Remaining 20% Interest in PhytoPain Pharma Inc.
Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TSX VENTURE: TBP)(OTCQB: TBPMF), today announced the completion of the previously announced acquisition of the remaining 20% interest in its PhytoPain Pharma Inc. subsidiary (the "Transaction") from entities controlled by Andre Rancourt, Chairman of the Board of Directors of the Corporation, and Guy Chamberland, Chief Scientific Officer of the Corporation (collectively, the "Sellers").
Mar 19, 2018 08:01 am ET
Tetra Bio-Pharma Completes Acquisition of Remaining 20% Interest in PhytoPain Pharma Inc.
Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TSX VENTURE:TBP)(OTCQB:TBPMF), today announced the completion of the previously announced acquisition of the remaining 20% interest in its PhytoPain Pharma Inc. subsidiary...
Mar 16, 2018 08:00 am ET
Tetra Bio-Pharma Inc. Announces a Non-Brokered Private Placement
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP)(OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced that it is conducting a non-brokered private placement of up to 4,500,000 units at a price of $1.00 per unit for aggregate gross proceeds of up to $4,500,000.
Mar 16, 2018 07:58 am ET
Tetra Bio-Pharma Inc. Announces a Non-Brokered Private Placement
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced that it is conducting a non-brokered private placement of up to 4,500,000 units at...
Mar 14, 2018 06:00 am ET
Tetra Bio-Pharma Announces FDA Orphan Drug Designation for PPP001 in Treatment of Complex Regional Pain Syndrome
Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TSX VENTURE: TBP)(OTCQB: TBPMF), today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the active ingredients of its PPP001 drug (delta-9-tetrahydrocannabinol 9.5% and cannabidiol 2.5%) for the treatment of complex regional pain syndrome (CRPS). The Orphan Drug Designation was granted for the active moiety of the drug PPP001 and not the formulation.
Mar 14, 2018 05:58 am ET
Tetra Bio-Pharma Announces FDA Orphan Drug Designation for PPP001 in Treatment of Complex Regional Pain Syndrome
Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TSX VENTURE:TBP)(OTCQB:TBPMF), today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the active ingredients of its PPP001 drug...
Mar 08, 2018 08:00 am ET
Tetra Bio-Pharma Signs Co-development and Distribution Partnership Term Sheet
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP)(OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce it has signed a co-development and distribution partnership term sheet with a major specialty healthcare distributor.
Mar 08, 2018 07:58 am ET
Tetra Bio-Pharma Signs Co-development and Distribution Partnership Term Sheet
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce it has signed a co-development and distribution partnership term sheet with...
Mar 06, 2018 08:00 am ET
Tetra Bio-Pharma Takes First Steps into European Medical Cannabis Market
Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TSX VENTURE: TBP)(OTCQB: TBPMF) announced today that its partner PS Innovations will be seeking CE Marking for its Rx Princeps(TM) Inhalation Device, thereby opening the door to Tetra's commercialization efforts in Europe.
Mar 06, 2018 07:58 am ET
Tetra Bio-Pharma Takes First Steps into European Medical Cannabis Market
Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TSX VENTURE:TBP)(OTCQB:TBPMF) announced today that its partner PS Innovations will be seeking CE Marking for its Rx Princeps™ Inhalation Device, thereby opening the door to Tetra's...
Mar 05, 2018 10:24 am ET
Tetra Bio-Pharma Announces Closing of Bought Deal Financing
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
Feb 26, 2018 08:00 am ET
Tetra Bio-Pharma names Aphria CFO as Chairman of Audit Committee
Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TSX VENTURE: TBP)(OTCQB: TBPMF), announced changes to its Board of Directors (the "Board") today, including the appointment of Aphria Inc.'s Chief Financial Officer (CFO), Mr. Carl Merton, as Chair of Tetra's Audit Committee.
Feb 26, 2018 07:58 am ET
Tetra Bio-Pharma names Aphria CFO as Chairman of Audit Committee
Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TSX VENTURE:TBP)(OTCQB:TBPMF), announced changes to its Board of Directors (the "Board") today, including the appointment of Aphria Inc.'s Chief Financial Officer (CFO), Mr. Carl Merton, as...
Feb 22, 2018 12:11 pm ET
Tetra Bio-Pharma Announces the Completion of GrowPros Transaction
OTTAWA, Feb. 22, 2018 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce the completion of the sale of its shares of...
Feb 12, 2018 08:00 am ET
Neptune and Tetra Bio-Pharma Enter Co-Development Agreement for Purified Cannabinoid Oil-Based Products targeting Pain and Inflammation
Tetra Bio-Pharma Inc. ("Tetra") (TSX VENTURE: TBP)(OTCQB: TBPMF) and Neptune Technologies & Bioressources Inc. ("Neptune") (NASDAQ: NEPT)(TSX: NEPT) today announced that they entered into an agreement for the co-development, commercialization and marketing of purified cannabinoid oil-based products to address pain and inflammation relief applications for the natural health products and pet veterinary markets.
Feb 12, 2018 08:00 am ET
Neptune and Tetra Bio-Pharma Enter Co-Development Agreement for Purified Cannabinoid Oil-Based Products targeting Pain and Inflammation
Neptune Technologies & Bioressources Inc. ("Neptune") (NASDAQ: NEPT)(TSX: NEPT) and Tetra Bio-Pharma Inc. ("Tetra") (TSX VENTURE: TBP)(OTCQB: TBPMF) today announced that they entered into an agreement for the co-development, commercialization and marketing of purified cannabinoid oil-based products to address pain and inflammation relief applications for the natural health products and pet veterinary markets.
Feb 12, 2018 07:58 am ET
Neptune and Tetra Bio-Pharma Enter Co-Development Agreement for Purified Cannabinoid Oil-Based Products targeting Pain and Inflammation
Tetra Bio-Pharma Inc. ("Tetra") (TSX VENTURE:TBP)(OTCQB:TBPMF) and Neptune Technologies & Bioressources Inc. ("Neptune") (NASDAQ:NEPT)(TSX:NEPT) today announced that they entered into an agreement for the co-development, commercialization...
Feb 12, 2018 07:58 am ET
Neptune and Tetra Bio-Pharma Enter Co-Development Agreement for Purified Cannabinoid Oil-Based Products targeting Pain and Inflammation
Neptune Technologies & Bioressources Inc. ("Neptune") (NASDAQ:NEPT)(TSX:NEPT) and Tetra Bio-Pharma Inc. ("Tetra") (TSX VENTURE:TBP)(OTCQB:TBPMF) today announced that they entered into an agreement for the co-development, commercialization and...
Feb 08, 2018 12:49 pm ET
Tetra Bio-Pharma Announces Upsizing of Previously Announced Offering
NOT FOR DISTRIBUTION TO THE U.S. NEWSWIRE OR FOR DISSEMINATION IN THE UNITED STATES
Feb 08, 2018 09:53 am ET
IIROC Trade Resumption - Tetra Bio-Pharma Inc.
Vancouver, British Columbia--(Newsfile Corp. - February 8, 2018) - Trading resumes in:
Feb 08, 2018 09:43 am ET
IIROC Trade Halt - Tetra Bio-Pharma Inc.
Vancouver, British Columbia--(Newsfile Corp. - February 8, 2018) - The following issues have been halted by IIROC:
Feb 08, 2018 09:36 am ET
Tetra Bio-Pharma Announces $8 million Bought Deal Offering
NOT FOR DISTRIBUTION TO THE U.S. NEWSWIRE OR FOR DISSEMINATION IN THE UNITED STATES
Feb 08, 2018 08:58 am ET
IIROC Trading Resumption - TBP
VANCOUVER, Feb. 8, 2018 /CNW/ - Trading resumes in:
Feb 08, 2018 08:36 am ET
IIROC Trading Halt - TBP
VANCOUVER, Feb. 8, 2018 /CNW/ - The following issues have been halted by IIROC:
Feb 05, 2018 08:00 am ET
RETRANSMISSION: Tetra Bio-Pharma Receives Health Canada Phase 3 Clinical Trial Approval For Smokable Dried Cannabis Prescription Drug
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP)(OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that it has received a No Objection Letter (NOL) from the Therapeutic Products Directorate (TPD) Health Canada to its Clinical trial application (CTA) for the Company's PPP001 prescription smokable dried cannabis product.
Feb 05, 2018 07:58 am ET
RETRANSMISSION: Tetra Bio-Pharma Receives Health Canada Phase 3 Clinical Trial Approval For Smokable Dried Cannabis Prescription Drug
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that it has received a No Objection Letter (NOL) from the Therapeutic...
Feb 04, 2018 12:00 pm ET
Tetra Bio-Pharma Receives Health Canada Phase 3 Clinical Trial Approval For Smokable Dried Cannabis Prescription Drug
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP)(OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that it has received a No Objection Letter (NOL) from the Therapeutic Products Directorate (TPD) Health Canada to its Clinical trial application (CTA) for the Company's PPP001 prescription smokable dried cannabis product.
Feb 04, 2018 11:58 am ET
Tetra Bio-Pharma Receives Health Canada Phase 3 Clinical Trial Approval For Smokable Dried Cannabis Prescription Drug
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that it has received a No Objection Letter (NOL) from the Therapeutic...
Jan 29, 2018 08:00 am ET
Tetra Bio-Pharma Receives Health Canada Approval for Phase 2 Cannabis Oil Trial in Partnership with Sante Cannabis
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP)(OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce the approval by Health Canada of a Phase 2 clinical trial designed to evaluate the safety and efficacy of different doses and ratios of medical cannabis oil (THC & CBD) to improve uncontrolled chronic pain in cancer and non-cancer patients.
Jan 29, 2018 07:58 am ET
Tetra Bio-Pharma Receives Health Canada Approval for Phase 2 Cannabis Oil Trial in Partnership with Sante Cannabis
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce the approval by Health Canada of a Phase 2 clinical trial designed to...
Jan 16, 2018 08:00 am ET
Tetra Bio-Pharma Receives Approval from Health Canada of its Phase 1 Clinical Trial with PPP005 (Cannabis Oil)
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP)(OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that it has received a No Objection Letter (NOL) from the Therapeutic Products Directorate (TPD), Health Canada to evaluate the safety, pharmacokinetics and pharmacodynamics of its cannabis oil PPP005.
Jan 16, 2018 07:58 am ET
Tetra Bio-Pharma Receives Approval from Health Canada of its Phase 1 Clinical Trial with PPP005 (Cannabis Oil)
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that it has received a No Objection Letter (NOL) from the Therapeutic...
Jan 02, 2018 08:00 am ET
Tetra Bio-Pharma Enters into Agreement to Acquire Remaining 20% Interest in Phytopain Pharma Subsidiary
Bio-Pharma Inc. ("Tetra" or the "Corporation") (TSX VENTURE: TBP)(OTCQB: TBPMF), a global leader in cannabinoid-based drug development, today announced that it has entered into a share purchase agreement (the "Purchase Agreement") with entities controlled by Andre Rancourt, Chairman of the Board of Directors of the Corporation, and Guy Chamberland, Chief Scientific Officer of the Corporation (collectively, the "Vendors").
Jan 02, 2018 07:58 am ET
Tetra Bio-Pharma Enters into Agreement to Acquire Remaining 20% Interest in Phytopain Pharma Subsidiary
Bio-Pharma Inc. ("Tetra" or the "Corporation") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development, today announced that it has entered into a share purchase agreement (the "Purchase Agreement") with entities...
Dec 21, 2017 08:00 am ET
Tetra Bio-Pharma Announces the Signature of a Letter of Intent to Monetize GrowPros and its Late Stage ACMPR Application
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP)(OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that it has entered into a non-binding letter of intent (the "LOI") with a private Canadian corporation (the "Purchaser") and has started a transaction to monetize GrowPros (GrowPros MMP Inc., Tetra's wholly-owned subsidiary) (the "Potential Transaction"), to allow Tetra to focus its activities on the drug development and its clinical trials of its pharmaceutical
Dec 21, 2017 07:58 am ET
Tetra Bio-Pharma Announces the Signature of a Letter of Intent to Monetize GrowPros and its Late Stage ACMPR Application
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that it has entered into a non-binding letter of intent (the "LOI") with a...
Dec 13, 2017 05:17 pm ET
Tetra Bio-Pharma Reinforces its Development Program by Signing Research & Development Agreement with Constance Therapeutics and Receiving Financial Support from NSERC
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that the company has signed an exclusive research and development (R&D)...
Dec 13, 2017 05:17 pm ET
Tetra Bio-Pharma Reinforces its Development Program by Signing Research & Development Agreement with Constance Therapeutics and Receiving Financial Support from NSERC
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP)(OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that the company has signed an exclusive research and development (R&D) agreement with Constance Therapeutics for the pharmaceutical drug development, and eventual commercialization in Canada, of their standardized, patent-pending, medicinal cannabis extract products. In addition to this agreement, the Company further strengthens its R&D program by means of a National Sciences and Engineering
Dec 09, 2017 12:00 pm ET
Tetra Bio-Pharma provides update on status of its Phase 3 Clinical Trial Application of Lead Drug Candidate PPP001
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP)(OTCQB: TBPMF), a global leader in cannabinoid-based drug development, announced today that the Company has accepted the suggestion of Health Canada to change the order of its clinical trial application (CTA) review process. As such, the quality certification for the manufacturing of PPP001 will take place prior to the approval of its clinical trial protocol as Health Canada assesses its partner Aphria's operations for Good Manufacturing Practices (GMP) for pharmaceutical products. Tetra agrees to this
Dec 09, 2017 11:58 am ET
Tetra Bio-Pharma provides update on status of its Phase 3 Clinical Trial Application of Lead Drug Candidate PPP001
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development, announced today that the Company has accepted the suggestion of Health Canada to change the order of its clinical...
Dec 06, 2017 02:01 pm ET
Tetra Bio-Pharma Opens Markets at TSX Listing Ceremony
Editors Note: There is a photo associated with this press release.
Dec 06, 2017 02:01 pm ET
Tetra Bio-Pharma Opens Markets at TSX Listing Ceremony
Editors Note: There is a photo associated with this press release. Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development, is pleased to announce that Tetra...
Dec 06, 2017 01:19 pm ET
Tetra Bio-Pharma Inc. Opens the Market
TORONTO, Dec. 5, 2017 /CNW/ - Bernard Fortier, CEO, Tetra Bio-Pharma Inc. (TBP), joined Tim Babcock, Director, Listed Issuer Services, TSX Venture Exchange, to open the market. Tetra Bio-Pharma biopharmaceutical company that is engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements. Tetra Bio-Pharma Inc. commenced trading on TSX Venture Exchange on August 16, 2017.
Nov 28, 2017 05:00 pm ET
Tetra Bio-Pharma accelerates submission of New Drug Application to FDA & Expects to Commercialize Dronabinol XL Tablet Ahead of Schedule(1) in the US
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP) (OTCQB: TBPMF), a global leader in cannabinoid-based drug development, today announced that it is partnering with a major manufacturer of controlled active pharmaceutical ingredients (APIs) in the USA for the manufacturing of Dronabinol XL AdVersa(R) as the Company accelerates its plans to submit a 505(b)(2) New Drug Application (NDA) for the treatment of chemotherapy-induced nausea and vomiting (CINV) and anorexia associated with weight loss in patients with AIDS.
Nov 28, 2017 04:58 pm ET
Tetra Bio-Pharma accelerates submission of New Drug Application to FDA & Expects to Commercialize Dronabinol XL Tablet Ahead of Schedule(1) in the US
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP) (OTCQB:TBPMF), a global leader in cannabinoid-based drug development, today announced that it is partnering with a major manufacturer of controlled active pharmaceutical ingredients...
Nov 22, 2017 05:02 pm ET
Tetra Bio-Pharma's Business Model and Commercialization Strategy In Line with the Canadian Government's Proposed Approach to the Regulation of Cannabis
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP)(OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced that the Canadian Government's Proposed Approach to the Regulation of Cannabis further confirms the strategic direction of its business model, and that the company is in an excellent position to commercialize natural health products and drugs post-legalization for both the pet and human markets.
Nov 22, 2017 05:02 pm ET
Tetra Bio-Pharma's Business Model and Commercialization Strategy In Line with the Canadian Government's Proposed Approach to the Regulation of Cannabis
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced that the Canadian Government's Proposed Approach to the Regulation of Cannabis...
Nov 16, 2017 07:30 am ET
Tetra Bio-Pharma Inc.: Rx Princeps(TM) Now Available for Patients through Licenced Producer Partner Aphria
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced that Rx Princeps™, unique blend of dried medical cannabis used in its PPP001...
Nov 16, 2017 07:30 am ET
Tetra Bio-Pharma Inc.: Rx Princeps(TM) Now Available for Patients through Licenced Producer Partner Aphria
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP)(OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced that Rx Princeps(TM), unique blend of dried medical cannabis used in its PPP001 clinical trials, is now available through licensed producer Aphria Inc. ("Aphria") under Access to Cannabis for Medical Purposes Regulations (ACMPR).
Nov 09, 2017 07:30 am ET
Tetra Bio-Pharma Concludes its First Sale of Rx Princeps(TM) Inhalation Device
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP)(OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced its first sale of its Rx Princeps(TM) inhalation device. The sale of this inhalation device is the first step towards the sale of Rx Princeps(TM).
Nov 09, 2017 07:28 am ET
Tetra Bio-Pharma Concludes its First Sale of Rx Princeps(TM) Inhalation Device
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced its first sale of its Rx Princeps™ inhalation device. The sale of this...
Oct 26, 2017 08:00 am ET
Tetra Bio-Pharma Goes After the Cannabis Oil Medical Market and Launches a Phase 4 Trial with Cannabis Oils in Partnership with Santé Cannabis
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP)(OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced the launch of a medical cannabis oil program as it targets penetrating the lucrative cannabis oil market and strengthens its plans to generate revenues from the medical cannabis market.
Oct 26, 2017 07:58 am ET
Tetra Bio-Pharma Goes After the Cannabis Oil Medical Market and Launches a Phase 4 Trial with Cannabis Oils in Partnership with Santé Cannabis
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced the launch of a medical cannabis oil program as it targets penetrating the...
Oct 19, 2017 08:00 am ET
Tetra Bio-Pharma Hires Medical Science Liaison to Promote Rx Princeps(TM) and Presents its New Corporate Image
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP)(OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced the hiring of Dr. Vincent Jourdain, Ph. D. as medical science liaison (MSL).
Oct 19, 2017 07:58 am ET
Tetra Bio-Pharma Hires Medical Science Liaison to Promote Rx Princeps(TM) and Presents its New Corporate Image
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced the hiring of Dr. Vincent Jourdain, Ph. D. as medical science liaison (MSL)....
Oct 18, 2017 08:00 am ET
Tetra Bio-Pharma Signs Agreement with Partner Aphria to Start Promoting Rx Princeps(TM), its Medical Cannabis Blend, under ACMPR
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP)(OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced that it will start promoting a co-developed medical cannabis blend product under Access to Cannabis for Medical Purposes Regulations (ACMPR). Tetra has signed a distribution agreement with its trusted partner Aphria to sell Rx Princeps(TM), its unique blend of dried medical cannabis used in its PPP0001 clinical trials. Production of Rx Princeps has been initiated and will be available to patients in the
Oct 18, 2017 07:58 am ET
Tetra Bio-Pharma Signs Agreement with Partner Aphria to Start Promoting Rx Princeps(TM), its Medical Cannabis Blend, under ACMPR
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced that it will start promoting a co-developed medical cannabis blend product under...
Oct 13, 2017 08:00 am ET
Tetra Bio-Pharma Continues Forward into the Veterinary Ophthalmology Market by Entering into an Agreement with Drs. Cullen and Webb
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP)(OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced the addition of two members to its clinical advisory board for the veterinary market - Dr. Cheryl Cullen, an American Board-certified Veterinary Ophthalmologist, and Dr. Webb, an American Board of Veterinary Ophthalmology (ABVO) Resident.
Oct 13, 2017 07:58 am ET
Tetra Bio-Pharma Continues Forward into the Veterinary Ophthalmology Market by Entering into an Agreement with Drs. Cullen and Webb
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced the addition of two members to its clinical advisory board for the veterinary...
Oct 04, 2017 05:00 pm ET
Tetra Bio-Pharma Selected to Present at Prestigious BIO Investor Forum In San Francisco October 17-18
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP)(OTCQB: TBPMF), a global leader in cannabinoid-based drug discovery, today announced that it has been selected, among a large group of candidates, to present at the prestigious BIO Investor Forum to be held in San Francisco October 17-18th at the Westin St. Francis Hotel. Robert (Bob) Bechard, Vice-President, Finance and Business Development of Tetra will present on Tuesday the 17th at 4:00pm Pacific Time (7:00pm Eastern Time). The presentation will be available live via webcast.
Sep 28, 2017 08:00 am ET
Tetra Engages in Innovative Air Analysis and Development of Specific Air Cleaning Devices with AES Environment for the Commercialization of PPP001 and for Marijuana Consumer Market
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP)(OTCQB: TBPMF), today announced that it has signed a letter of intent (LOI) with AES Environment Group to develop and commercialize specific products ensuring the safety of caregivers for patients who will use PPP001 or medical cannabis.
Sep 28, 2017 07:58 am ET
Tetra Engages in Innovative Air Analysis and Development of Specific Air Cleaning Devices with AES Environment for the Commercialization of PPP001 and for Marijuana Consumer Market
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), today announced that it has signed a letter of intent (LOI) with AES Environment Group to develop and commercialize specific products ensuring the safety of caregivers...
Sep 20, 2017 08:00 am ET
Tetra Bio-Pharma to engage in co-development and distribution partnership with major healthcare specialty distributor
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP)(OTCQB: TBPMF), today announced that it has signed a letter of intent (LOI) with a major player of the healthcare specialty industry.
Sep 20, 2017 07:58 am ET
Tetra Bio-Pharma to engage in co-development and distribution partnership with major healthcare specialty distributor
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), today announced that it has signed a letter of intent (LOI) with a major player of the healthcare specialty industry. This privately-owned partner, which asked...
Sep 18, 2017 08:00 am ET
Tetra Bio-Pharma getting ready to file a clinical trial application to initiate phase 3 clinical trial on terminal cancer patients in the coming weeks
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP)(OTCQB: TBPMF), today announces that it will be filing a clinical trial application (CTA) in the coming weeks to therapeutic products directorate (TPD) to initiate its Phase 3 clinical trial of PPP001 in terminal cancer patients. With this filing, Tetra expects to be on time with its previously announced schedule with the development of PPP001. The corporation worked with physicians of Sante Cannabis to design a clinical trial that would demonstrate the safety and efficacy of PPP001 in terminal cancer
Sep 18, 2017 07:58 am ET
Tetra Bio-Pharma getting ready to file a clinical trial application to initiate phase 3 clinical trial on terminal cancer patients in the coming weeks
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), today announces that it will be filing a clinical trial application (CTA) in the coming weeks to therapeutic products directorate (TPD) to initiate its Phase...
Sep 11, 2017 07:00 am ET
Tetra Bio-Pharma accelerates its clinical research program in the veterinary market by entering into agreement with Dr. Louis-Philippe de Lorimier
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP)(OTCQB: TBPMF), today announced that it has added international expert Dr. Louis-Philippe de Lorimier, a board certified veterinary oncologist, to its clinical advisory board for the veterinary market.
Sep 11, 2017 06:58 am ET
Tetra Bio-Pharma accelerates its clinical research program in the veterinary market by entering into agreement with Dr. Louis-Philippe de Lorimier
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), today announced that it has added international expert Dr. Louis-Philippe de Lorimier, a board certified veterinary oncologist, to its clinical advisory board for...
Sep 07, 2017 05:00 pm ET
Tetra Bio-Pharma to Attend the 10th Annual International Partnering Conference - BioPharm America
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP)(OTCQB: TBPMF), a global leader in cannabinoid-based drug discovery, today announced that its Vice President of Business Development, Mr. Bob Bechard, is scheduled to attend the 10th Annual International Partnering Conference, BioPharm America, September 26-27 at the Sheraton Boston Hotel.
Sep 07, 2017 04:58 pm ET
Tetra Bio-Pharma to Attend the 10th Annual International Partnering Conference - BioPharm America
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug discovery, today announced that its Vice President of Business Development, Mr. Bob Bechard, is scheduled to attend the 10th...
Aug 31, 2017 05:00 pm ET
Tetra Bio-Pharma to Benefit from Intellectual Properties Created within the Cannabis Health Research Chair from the University of New Brunswick
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP) (OTCQB: TBPMF), today announced that it will benefit from the intellectual property (IP) created within the cannabis health research Chair (The Chair) from the University of New Brunswick (UNB). The Corporation also provided a corporate update.
Aug 31, 2017 04:58 pm ET
Tetra Bio-Pharma to Benefit from Intellectual Properties Created within the Cannabis Health Research Chair from the University of New Brunswick
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP) (OTCQB:TBPMF), today announced that it will benefit from the intellectual property (IP) created within the cannabis health research Chair (The Chair) from the University of New...
Aug 29, 2017 08:00 am ET
Tetra Bio-Pharma Strengthens its Management Team in Preparation for the Initiation of its Commercial Activities
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP)(OTCQB: TBPMF) today announced that it has strengthened its management team in preparation for the initiation of its commercial activities with the appointments of Dr. Anne-Sophie Courtois to the position of Vice President, Marketing effective immediately and Mr. Bernard Lessard to the position of Chief Financial Officer (CFO), effective September 18, 2017. Mr. Lessard will be replacing Mr. Sabino Di Paola as CFO of the corporation.
Aug 29, 2017 07:58 am ET
Tetra Bio-Pharma Strengthens its Management Team in Preparation for the Initiation of its Commercial Activities
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF) today announced that it has strengthened its management team in preparation for the initiation of its commercial activities with the appointments of Dr. Anne-Sophie...
Aug 16, 2017 08:00 am ET
Tetra Bio-Pharma Announces Approval to List on the TSX Venture Exchange
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE: TBP)(CSE: TBP.CN)(CNSX: TBP)(TSX VENTURE: TBP)(OTCQB: TBPMF), today announced that its common shares have been approved for trading on the TSX Venture Exchange and that it has applied for voluntary delisting of its common shares from the Canadian Securities Exchange (CSE). Tetra's shares will commence trading on the TSX Venture on the opening of markets on Wednesday, August 16, 2017, under the symbol "TBP".
Aug 16, 2017 07:58 am ET
Tetra Bio-Pharma Announces Approval to List on the TSX Venture Exchange
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(TSX VENTURE:TBP)(OTCQB:TBPMF), today announced that its common shares have been approved for trading on the TSX Venture Exchange and that it has applied for voluntary...
Jul 26, 2017 02:33 pm ET
Tetra Bio-Pharma CSO Discusses Opportunities in Exclusive CFN Media Interview
CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article and exclusive interview covering Tetra Bio-Pharma Inc. (CSE: TBP) (CSE: TBP.CN) (CNSX: TBP) (OTCQB: TBPMF). The interview, with Chief Science Officer Dr. Guy Chamberland, and article discuss the company's progress in advancing its clinical pipeline designed to bring innovative cannabis products to market. With a new CEO and new partnerships, these efforts could be accelerated over the coming quarters as the company gears up for pivotal
Jul 25, 2017 05:00 pm ET
Tetra Bio-Pharma Announces Stock Option Grant to CEO
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE: TBP)(CSE: TBP.CN)(CNSX: TBP)(OTCQB: TBPMF), announces that it has made a grant of stock options under its stock option plan to the newly appointed Chief Executive Officer, Bernard Fortier to acquire a total of 400,000 common shares of the Company. All of the options are exercisable at a price of $0.80 per share. All of the options will vest immediately of the date of grant. The options have a term of 4 years and are subject in all respects to the terms of Tetra's stock option plan.
Jul 25, 2017 04:58 pm ET
Tetra Bio-Pharma Announces Stock Option Grant to CEO
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF), announces that it has made a grant of stock options under its stock option plan to the newly appointed Chief Executive Officer, Bernard Fortier to acquire...
Jul 24, 2017 08:30 am ET
Tetra Bio-Pharma Accelerates Growth Strategy with Appointment of Bernard Fortier as CEO
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE: TBP)(CSE: TBP.CN)(CNSX: TBP)(OTCQB: TBPMF) today announced that it has strengthened its management team with the appointment of Bernard Fortier to the position of Chief Executive Officer, effective today, July 24, 2017. Mr. Andre Rancourt, previous interim CEO will take the position as Chairman of the Board of Directors. Mr. Andre Audet will step down as Chairman of the Board of Directors but will continue to serve as a Board member.
Jul 24, 2017 08:28 am ET
Tetra Bio-Pharma Accelerates Growth Strategy with Appointment of Bernard Fortier as CEO
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF) today announced that it has strengthened its management team with the appointment of Bernard Fortier to the position of Chief Executive Officer, effective...
Jul 19, 2017 08:00 am ET
Tetra Bio-Pharma Signs Letter of Intent with Constance Therapeutics
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE: TBP)(CSE: TBP.CN)(CNSX: TBP)(OTCQB: TBPMF), announced today it has signed a Letter of Intent (LOI) with Constance Therapeutics, Inc. of San Francisco, California, USA, for the clinical development and commercialization in Canada of its signature standardized, patent-pending, medicinal cannabis extract products.
Jul 19, 2017 07:58 am ET
Tetra Bio-Pharma Signs Letter of Intent with Constance Therapeutics
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF), announced today it has signed a Letter of Intent (LOI) with Constance Therapeutics, Inc. of San Francisco, California, USA, for the clinical development...
Jul 11, 2017 05:00 pm ET
Tetra Bio-Pharma Announces Results of Voting at Annual Shareholders' Meeting & Provides a Corporate Update
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE: TBP)(CSE: TBP.CN)(CNSX: TBP)(OTCQB: TBPMF), is pleased to announce the results of the vote at its July 10, 2017 annual shareholders' meeting.
Jul 11, 2017 04:58 pm ET
Tetra Bio-Pharma Announces Results of Voting at Annual Shareholders' Meeting & Provides a Corporate Update
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF), is pleased to announce the results of the vote at its July 10, 2017 annual shareholders' meeting....
Jul 06, 2017 05:00 pm ET
CORRECTION - Tetra Bio-Pharma: Defending & Validating Smoked Cannabis -- CFN Media
In the news release, "Tetra Bio-Pharma: Defending & Validating Smoked Cannabis -- CFN Media," issued earlier today by CFN Media, we are advised by the company that the Tetra Bio-Pharma Inc. ticker in the first paragraph should read "(OTCQB: TBPMF)" rather than "(OTC: GRPOF)" as originally issued. Complete corrected text follows.
Jul 06, 2017 09:00 am ET
Tetra Bio-Pharma: Defending & Validating Smoked Cannabis -- CFN Media
CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, announces publication of an exclusive interview and article discussing Tetra Bio-Pharma Inc. (CNSX: TBP) (OTC: GRPOF) and its clinical approach to defending the use of dried marijuana to treat patients in Canada.